Over the last decade, several studies have investigated the role of glucose-lowering drugs in cardiovascular outcomes, especially glucagon-like peptide-1 receptor agonists (GLP1-RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) which have demonstrated substantial improvements in major cardiovascular events, kidney function outcomes, and hospitalizations [3]
This study suggests that GLP-1 receptor agonist therapy is associated with a higher risk of smell and taste disturbance, highlighting the need for closer monitoring and greater public health awareness, the researchers wrote, before stressing that future research is needed
Individuals who have gotten these resources are going to continue to utilize these products. After the meeting, the FDA will review the votes, discussion and public comments before making a decision on each of the peptides
PMID: 23466817
Eur J Clin Invest (1992) 22(10):68791.10.1111/j.1365-2362.1992.tb01431.x 136 KremerJMLawrenceDAPetrilloGFLittsLLMullalyPMRynesRIet alEffects of high-dose fish oil on rheumatoid arthritis after stopping nonsteroidal antiinflammatory drugs clinical and immune correlates
